The researchers think that BN83495 may be better than megace to treat women with womb cancer that is advanced or has come back after treatment. The aims of this trial are to find out how well BN83495 works for women with womb cancer that is advanced or has come back, how safe BN83495 is for these women and ow it affects their quality of life

• Conditions: MedDRA version: 14.1Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]; Advanced or recurrent endometrial cancer

• Registration Number: EUCTR2009-010613-68-CZ
• Lead Sponsor: Ipsen Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-07-02
• Last Update Posted: 3 February 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

1. Provision of written informed consent prior to any study related procedures.
2. Post-menopausal or ovariectomised female patients over the age of 18 years with advanced or recurrent endometrial cancer.
3. Histologically confirmed diagnosis of endometrial carcinoma (primary tumour or metastasis).
4. Not eligible for surgery or radiotherapy alone, at Investigator’s discretion.
5. Document ER positivity in the primary tumour or in the metastatic tissue if the primary tumour is unavailable (ER positivity is defined by at least 10% positive cells).
6. No other history of malignant disease except treated basal cell or in situ cervical carcinoma in the previous 5 years. In case of previous malignant disease, pathological confirmation of metastatic endometrial cancer will be done at Investigator’s discretion.
7. Eastern Cooperative Oncology Group (ECOG) performance status =2.
8. At least one measurable disease site (RECIST criteria version 1.0)
- minimum indicator lesion size: 20mm (conventional techniques) or 10mm (spiral CT scan)
- target lesions not situated in irradiated area
9. Life expectancy =6 months.
10. Adequate organ function as defined by the following criteria:
- Haemogolobin =10g/dL
- Absolute neutrophil count (ANC) =1500/µL
- Platelets =100,000/µl
- Serum creatinine =1.5x upper limit of normal (ULN) or calculated creatinine clearance =50 mL/min
- Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) =2.5x ULN or AST and ALT =5x ULN if liver metastases
- Total serum bilirubin =1.5x ULN
- Serum albumin =3.0 g/dL
- Cardiac function =New York Heart Association class II
11. Patients must have recovered from surgery, radiotherapy and toxicities of adjuvant chemotherapy treatment if applicable.
12. Patients must be willing and able to participate in a clinical trial (including the completion of all necessary study procedures).
13. Patients must be able to swallow oral medication.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 28
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 45

Exclusion Criteria

1. Use of any investigational agent in the 4 weeks prior to enrolment in this study
2. Prior systemic treatment for endometrial cancer (including hormonal treatment, chemotherapy, antiangiogenic or targeted therapies) with the exception of chemotherapy in the adjuvant setting having been completed at least 6 months prior to randomisation.
3. Known central nervous system (CNS) metastases
4. Ongoing cardiac dysrhythmias of NCI-CTC adverse event (AE) grade =2, or atrial fibrillation of any grade, or QT interval corrected for heart rate using Fridericia's formulas (QTcF) interval >460 msec
5. Patients with contraindications to MA including hypersensitivity to one of the components of the drug product, any active arterial or venous thromboembolic event and/or uncontrolled hypertension. Patients receiving anticoagulation for a prior thromboembolic event may be enrolled in the study at Investigator’s discretion
6. Concomitant use of systemic carbonic anhydrase II inhibitors (e.g. acetazolamide, dichlorphenamide, methazolamide).
7. History of hypersensitivity to BN83495 or drugs with a similar chemical structure.
8. Likely to require treatment during the study with drugs that are not permitted by the study protocol (see Section 9.7).
9. Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified